Advanced glycation endproducts link inflammatory cues to upregulation of galectin-1 in diabetic retinopathy
Atsuhiro Kanda, Yoko Dong, Kousuke Noda, Wataru Saito, and Susumu Ishida



Supplementary Figure S1. Preferential induction of *LGALS1* and *VEGF165* mRNAs by IL-1β and hypoxia, respectively

A, B, MIO-M1 was stimulated with IL-1β (10 ng/ml) and/or hypoxia condition (1% O_2) for 6-24 hours, and *LGALS1* (**A**) and *VEGF165* (**B**) gene expression levels were analyzed. $^{**}p < 0.01$ (n = 6 per group).

Advanced glycation endproducts link inflammatory cues to upregulation of galectin-1 in diabetic retinopathy
Atsuhiro Kanda, Yoko Dong, Kousuke Noda, Wataru Saito, and Susumu Ishida



Supplementary Figure S2. *LGALS1* expression in Müller glial cells via p38 MAPK
MIO-M1 was pretreated with SB203580 (10 μM) for 30 minutes before stimulation with or without IL-1β (10 ng/ml) for 24 hours, and *LGALS1* gene expression levels were analyzed. *$p < 0.05$, **$p < 0.01$ (n = 8 per group).

Advanced glycation endproducts link inflammatory cues to upregulation of galectin-1 in diabetic retinopathy
Atsuhiro Kanda, Yoko Dong, Kousuke Noda, Wataru Saito, and Susumu Ishida



Supplementary Figure S3. Full-length blots of Figure 3D

Advanced glycation endproducts link inflammatory cues to upregulation of galectin-1 in diabetic retinopathy
Atsuhiro Kanda, Yoko Dong, Kousuke Noda, Wataru Saito, and Susumu Ishida



Supplementary Figure S4. Unelevated expression of *IL1B* following AGE administration to retinal vascular endothelial cells
HRMEC was treated with AGE-BSA (10-400 μg/ml) for 24 hours, and *IL1B* expression levels were analyzed. (n = 8 per group)

Advanced glycation endproducts link inflammatory cues to upregulation of galectin-1 in diabetic retinopathy
Atsuhiro Kanda, Yoko Dong, Kousuke Noda, Wataru Saito, and Susumu Ishida



Supplementary Figure S5. Full-length blots of Figure 4F

Advanced glycation endproducts link inflammatory cues to upregulation of galectin-1 in diabetic retinopathy
Atsuhiro Kanda, Yoko Dong, Kousuke Noda, Wataru Saito, and Susumu Ishida





Supplementary Figure S6. Full-length blots of Figure 5F

Advanced glycation endproducts link inflammatory cues to upregulation of galectin-1 in diabetic retinopathy
Atsuhiro Kanda, Yoko Dong, Kousuke Noda, Wataru Saito, and Susumu Ishida



Supplementary Figure S7. Full-length gels of Figure 7M

Advanced glycation endproducts link inflammatory cues to upregulation of galectin-1 in diabetic retinopathy
Atsuhiro Kanda, Yoko Dong, Kousuke Noda, Wataru Saito, and Susumu Ishida



Supplementary Figure S8. *VEGF165* mRNA expression following DR-related stimuli to Müller glial cells, retinal vascular endothelial cells and macrophages

A-C, MIO-M1 (**A**), HRMEC (**B**) and THP-1 (**C**) were incubated with the medium containing 30-mM glucose for indicated time intervals, and *VEGF165* gene expression levels were analyzed. **D-F,** MIO-M1 (**D**), HRMEC (**E**) and THP-1 (**F**) were treated with IFN-γ (100 ng/ml), IGF-I (100 ng/ml), IL-12 (10 ng/ml), IL-1β (10 ng/ml) for 24 hours, and *VEGF165* expression levels were analyzed. **G-I,** MIO-M1 (**G**), HRMEC (**H**) and THP-1 (**I**) were treated with AGE-BSA (10-400 μg/ml) for 24 hours, and *VEGF165* expression levels were analyzed. $*p < 0.05$, $**p < 0.01$ (n = 8 per group).